Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics

Terns Pharmaceuticals, Inc. (TERN): $9.88

-0.21 (-2.08%)

POWR Rating

Component Grades














  • Growth is the dimension where TERN ranks best; there it ranks ahead of 65.62% of US stocks.
  • TERN's strongest trending metric is Sentiment; it's been moving down over the last 178 days.
  • TERN's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).

TERN Stock Summary

  • For TERN, its debt to operating expenses ratio is greater than that reported by only 7.04% of US equities we're observing.
  • With a price/sales ratio of 379.52, TERNS PHARMACEUTICALS INC has a higher such ratio than 98.89% of stocks in our set.
  • TERN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 6.86% of US stocks.
  • If you're looking for stocks that are quantitatively similar to TERNS PHARMACEUTICALS INC, a group of peers worth examining would be UBX, BCYC, EFTR, DCPH, and VLN.
  • Visit TERN's SEC page to see the company's official filings. To visit the company's web site, go to www.ternspharma.com.

TERN Valuation Summary

  • In comparison to the median Healthcare stock, TERN's EV/EBIT ratio is 183.97% lower, now standing at -5.5.
  • TERN's price/sales ratio has moved NA NA over the prior 26 months.

Below are key valuation metrics over time for TERN.

Stock Date P/S P/B P/E EV/EBIT
TERN 2023-03-17 379.5 2.1 -6.5 -5.5
TERN 2023-03-16 373.5 2.0 -6.4 -5.4
TERN 2023-03-15 346.4 1.9 -5.9 -4.9
TERN 2023-03-14 363.0 2.0 -6.2 -5.2
TERN 2023-03-13 352.4 1.9 -6.0 -5.0
TERN 2023-03-10 343.0 1.9 -5.8 -4.8

TERN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TERN has a Quality Grade of C, ranking ahead of 30.41% of graded US stocks.
  • TERN's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TERN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0 NA -5.557

TERN Price Target

For more insight on analysts targets of TERN, see our TERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.5 (Moderate Buy)

TERN Stock Price Chart Interactive Chart >

Price chart for TERN

TERN Price/Volume Stats

Current price $9.88 52-week high $11.44
Prev. close $10.09 52-week low $1.45
Day low $9.69 Volume 287,000
Day high $10.42 Avg. volume 289,660
50-day MA $9.50 Dividend yield N/A
200-day MA $6.00 Market Cap 371.63M

Terns Pharmaceuticals, Inc. (TERN) Company Bio

Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.

TERN Latest News Stream

Event/Time News Detail
Loading, please wait...

TERN Latest Social Stream

Loading social stream, please wait...

View Full TERN Social Stream

Latest TERN News From Around the Web

Below are the latest news stories about TERNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TERN as an investment opportunity.

Investing in Terns Pharmaceuticals (NASDAQ:TERN) a year ago would have delivered you a 211% gain

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you...

Yahoo | March 8, 2023

Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; on track to initiate first-in-human clinical t

Yahoo | March 2, 2023

TipRanks ‘Perfect 10’ List: 3 Top-Rated Stocks That Tick All the Right Boxes

This year started off gangbusters, with strong across-the-board gains for stocks in January – and it’s been followed in February by moderate losses, as stocks first leveled off and now are trending down. The market shifts have investors worried that last year’s volatility is still with us, making for an unpredictable market environment. And it has those same investors looking for a way to cut through the data ‘noise’ and find the right stocks for an unsettled time. TipRanks’ Smart Score is just

Yahoo | February 26, 2023

Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great Choice

Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | February 8, 2023

Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m.

Yahoo | February 2, 2023

Read More 'TERN' Stories Here

TERN Price Returns

1-mo -6.79%
3-mo 15.96%
6-mo 102.04%
1-year 225.00%
3-year N/A
5-year N/A
YTD -2.95%
2022 43.99%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7033 seconds.